All News
Filter News
Found 73,949 articles
-
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
4/5/2024
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
-
A Delaware judge on Wednesday agreed with Roivant subsidiary Arbutus and Genevant’s interpretation of specific patent claims regarding the lipid nanoparticle delivery system used by Moderna’s COVID-19 vaccine.
-
The American Association for Cancer Research has invited drug developers and investors to intermingle with the academics who typically attend its annual conference.
-
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
4/4/2024
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2024, which ended February 29, 2024.
-
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
4/4/2024
STAAR Surgical Company today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.
-
Oncology Clinical Trials Market Experiencing Rapid Growth
4/4/2024
The global oncology clinical trials market size was valued at USD 13.19 billion in 2023 and is projected to reach USD 22.11 Billion by 2033, growing at a CAGR of 5.3 % from 2024 to 2033. North America dominated the market and accounted for the largest revenue share of 43% in 2023.
-
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
4/4/2024
Recce Pharmaceuticals Ltd today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
-
Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
4/4/2024
Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor.
-
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
4/4/2024
Arbutus Biopharma Corporation today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plaintiffs) against Moderna.
-
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
4/4/2024
Allarity Therapeutics, Inc. today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”).
-
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
4/4/2024
Co-Diagnostics, Inc. today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO).
-
ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis
4/4/2024
ANI Pharmaceuticals, Inc. https://www.anipharmaceuticals.com/ is proud to support the Foundation for Sarcoidosis Research’s commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.
-
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
4/4/2024
AngioDynamics, Inc. announced that the United States Food and Drug Administration has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism, enhancing its utility in critical medical scenarios such as PE.
-
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
4/4/2024
Invivyd, Inc., a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced that PEMGARDA™ is now available for purchase in the U.S.
-
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
4/4/2024
Werewolf Therapeutics, Inc. announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists taking place May 3-7 in Chicago, Illinois.
-
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4/4/2024
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with GSK.
-
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
4/4/2024
Trinity Biotech plc today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
-
Results of the Combined General Meeting on April 2, 2024
4/4/2024
Biophytis SA announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting.
-
Henry Schein Completes Acquisition of Majority Interest of TriMed, Inc.
4/4/2024
Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced it has completed the acquisition of TriMed, Inc., a global developer of solutions for the orthopedic treatment of lower extremities and upper extremities.
-
Immunic to Host MS R&D Day and Participate in Investor Conferences in April 2024
4/4/2024
Immunic, Inc. announced that it will host a Multiple Sclerosis Research and Development Day and participate in the following investor conferences in April.